Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1407-1412

  Roman, Doina ^a   Bramson, Candace ^b   Quellet, Daniele ^b   Randinitis, Edward ^b   Gardner, Mark ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Digoxin; Drug interaction; Lasofoxifene; Osteoporosis; Postmenopausal women; SERM

Indexed keywords

DIGOXIN; LASOFOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LIQUID CHROMATOGRAPHY; MULTIPLE DRUG DOSE; NORMAL HUMAN; OSTEOPOROSIS; PHARMACOKINETICS; POSTMENOPAUSE; SOMNOLENCE; STEADY STATE; TANDEM MASS SPECTROMETRY; THORAX PAIN;

AGED; ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; DIGOXIN; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 27844504738     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005282627     Document Type: Article

References (16)

1. Rosati RL, Da Silva JP, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998;41:2928-2931.
2. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004;145:1996-2005.
3. Koren G. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin Pharmacokinet. 1987;13:334-343.
4. Steiness E. Renal tubular secretion of digoxin. Circulation. 1974;50:103-107.
5. Gibson TP, Ribner HS, Quintanilla AP. Effect of acute changes in serum digoxin concentrations on renal digoxin clearance. Clin Pharmacol Ther. 1984;36:478-484.
6. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F. Digoxin-verapamil interaction. Clin Pharmacol Ther. 1981;30:311-316.
7. Moysey JO, Jaggarao NS, Grundy EN, Chamberlain DA. Amiodarone increases plasma digoxin concentrations. BMJ. 1981;282:272-273.
8. Belz GG, Doering W, Munkes R, Matthews J. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther. 1983;33:410-417.
9. 1). J Pharmacol Exp Ther. 1992;263:840-845.
10. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J Clin Pharmacol. 2000;40:91-98.
11. Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther. 2000;68:6-12.
12. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003;73:223-231.
13. Tanaka H, Matsumoto K, Ueno K, et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother. 2003;37:178-181.
14. Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med. 2004;2:8.
15. Evista (raloxifene hydrochloride 60 mg tablets) [product information]. Indianapolis, Ind: Eli Lilly and Company; 2003.
16. Tamoxifen (systemic) [Medline Plus Web site]. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202545.html#SXX32. Accessed May 3, 2005.